About: Resveratrol plus carboxymethyl-β-glucan in infants with common cold: A randomized double-blind trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Resveratrol plus carboxymethyl-β-glucan in infants with common cold: A randomized double-blind trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Resveratrol plus carboxymethyl-β-glucan in infants with common cold: A randomized double-blind trial
Creator	Mastromarino, Paola Schiavi, Elisa Baldassarre, Maria Capozza, Manuela Fanelli, Margherita Labellarte, Grazia Laforgia, Nicola Mauro, Antonio Panza, Raffaella Pignatelli, Mariacristina
Source	Elsevier; Medline; PMC
abstract	OBJECTIVES: To evaluate effectiveness of a nasal resveratrol/carboxymethyl-β-glucan solution compared to nasal saline solution: a) on common cold symptoms by means of a validated measure scale (CARIFS score), b) on Rhinovirus infection and CCL2, CCL5, IL8, IL6, CXCL10 and TLR2 expression in nasal swabs, c) on frequency of relapses after 30 days of follow-up. METHODS: 89 infants with respiratory infection symptoms were randomly assigned to receive either a nasal resveratrol/carboxymethyl-β-glucan solution or nasal saline solution. All patients were evaluated with CARIFS score at enrollment, after 48 h, 7 and 30 days by physicians and parents. Nasal swabs were obtained at enrollment, after 48 h and after one week. RESULTS: CARIFS score improved in both groups. Episodes of sneezing and cough were fewer in study group after 7 days of follow-up (p < 0.05). No significant differences were found on nasopharyngeal swabs in Rhinovirus detection and cytokines expression after 48 h, nor in 30 days relapses. TLR2 expression was significantly higher in Rhinovirus infected children of the study group. No adverse effects occurred. CONCLUSIONS: These data suggest that a solution containing resveratrol plus carboxymethyl-β-glucan might have a positive impact on both clinical and socio-economic burden due to infant common cold.
has issue date	2020-04-21(xsd:dateTime)
bibo:doi	10.1016/j.heliyon.2020.e03814
bibo:pmid	32322697
has license	no-cc
sha1sum (hex)	5ff9a465e9df120322356d9b3af7427c7830cba6
schema:url	https://doi.org/10.1016/j.heliyon.2020.e03814
resource representing a document's title	Resveratrol plus carboxymethyl-β-glucan in infants with common cold: A randomized double-blind trial
has PubMed Central identifier	PMC7172624
has PubMed identifier	32322697
schema:publication	Heliyon
resource representing a document's body	covid:5ff9a465e9df120322356d9b3af7427c7830cba6#body_text
is schema:about of	named entity 'impact' named entity 'evaluated' named entity 'solution' named entity 'study group' named entity 'physicians' named entity 'Results' named entity 'RHINOVIRUS' named entity 'RESULTS' named entity 'OBTAINED' named entity 'VALIDATED' named entity 'SALINE SOLUTION' named entity 'CARBOXYMETHYL' named entity 'AND COUGH' named entity 'ENROLLMENT' named entity 'ASSIGNED' named entity 'SIGNIFICANT' named entity 'INFANT' named entity 'infected' named entity 'Rhinovirus' named entity 'study group' named entity 'nasal' named entity 'patients' named entity 'randomly assigned' named entity 'symptoms' named entity 'nasal' named entity 'double-blind trial' named entity 'CCL5' named entity 'β-glucan' named entity 'common cold' named entity 'TLR2' named entity 'sneezing' named entity 'respiratory infection' named entity 'Rhinovirus' named entity 'β-glucan' named entity 'Resveratrol' named entity 'common cold' named entity 'receive' named entity 'common cold' named entity 'anti-inflammatory' named entity 'β-glucan' named entity 'RNase' named entity 'Medical Device' named entity 'interferon-β' named entity 'HRV' named entity 'viruses' named entity 'HRV' named entity 'TLR-2' named entity 'evolution' named entity 'mucosa' named entity 'placebo group' named entity 'San Diego' named entity 'RANTES' named entity 'resveratrol' named entity 'hMPV' named entity 'RSV' named entity 'resveratrol' named entity 'epithelial cells' named entity 'viruses' named entity 'nQuery Advisor' named entity 'placebo' named entity 'colds' named entity 'chronic diseases' named entity 'clinicaltrials.gov' named entity 'resveratrol' named entity 'antiviral' named entity 'viruses' named entity 'Bari' named entity 'inflammatory conditions' named entity 'infection' named entity 'TLR-2' named entity 'common cold' named entity 'symptom'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software